MEDICINE DETAILS
Trelegy
Active ingredient: Ellipta Fluticasone Furoate Umeclidinium Vilanterol
Neutral reference profile for an independent medicine-access consultancy enquiry about Trelegy (Ellipta Fluticasone Furoate Umeclidinium Vilanterol). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Trelegy used for?
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a combination medication used for the long-term, once-daily, maintenance treatment of:
- Patients with chronic obstructive pulmonary disease (COPD), including:
- Patients with chronic bronchitis and/or emphysema
- Patients on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired
- Patients who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol
- Asthma in patients aged 18 years and older.
It is available in inhaler form containing 2 foil strips, each with 30 blisters with powder intended for oral inhalation. One strip contains 100 or 200 mcg fluticasone furoate per blister, and the other strip contains a combination of 62.5 mcg umeclidinium and 25 mcg vilanterol per blister. A blister from each strip is used to create one dose.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Trelegy identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
92 mcg/55 mcg/22 mcg · 30 doses per inhaler · 1 inhaler Catalogue organisation: GlaxoSmithKline GmbH & Co. KG
-
92 mcg/55 mcg/22 mcg · 30 doses per inhaler · 3 inhalers Catalogue organisation: GlaxoSmithKline GmbH & Co. KG
OFFICIAL SOURCES
Check the Trelegy record at an official source.
Search for “Trelegy” or “Ellipta Fluticasone Furoate Umeclidinium Vilanterol”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Trelegy.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Trelegy
01What is Trelegy?＋
This directory record associates the brand name Trelegy with the active ingredient Ellipta Fluticasone Furoate Umeclidinium Vilanterol. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Trelegy strengths and packs are recorded?＋
The catalogue currently shows: 92 mcg/55 mcg/22 mcg · 30 doses per inhaler · 1 inhaler; 92 mcg/55 mcg/22 mcg · 30 doses per inhaler · 3 inhalers. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Trelegy?＋
Catalogue records currently name: GlaxoSmithKline GmbH & Co. KG. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Trelegy?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Trelegy, payment request, stock guarantee or binding offer.
06Can I buy Trelegy from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.